{"entity":{"id":"nct06106945","kind":"trial","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of Elranatamab, Pomalidomide, Dexamethasone in multiple myeloma, run by AstraZeneca, now recruiting.","summary":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma is a phase 1/2 interventional study registered as NCT06106945 by AstraZeneca, with 226 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-08-16. Interventions recorded: AZD0305, Elranatamab, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06106945","url":"https://clinicaltrials.gov/study/NCT06106945"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["elranatamab","pomalidomide","dexamethasone"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06106945","phase":"1/2","setting":"A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma","sponsor":"AstraZeneca","participation":[{"nct":"NCT06106945","source":"https://clinicaltrials.gov/study/NCT06106945","fetchedAt":"2026-10-07T16:54:11.803Z","studySha256":"82b3dfa878738153e3db67c49ece93db43e2354eee2347abb0e7df7d8f0371ec","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-19","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":226,"enrolmentType":"ESTIMATED","siteCount":43,"recruitingSiteCount":32,"countries":["Australia","Brazil","Canada","China","France","Germany","Japan","Spain","United States"]}],"started":"2023-12-05","startedType":"actual","enrolled":226,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06106945/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}